Impact of interferon alfa‐2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C
暂无分享,去创建一个
G. Davis | P. Bedossa | Z. Goodman | J. McHutchison | T. Poynard | J. Albrecht | R. Esteban-Mur | J. Mchutchison
[1] Z. Goodman,et al. Is an “à la carte” combination interferon alfa‐2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? , 2000, Hepatology.
[2] C. Garret,et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. , 1999, Gastroenterology.
[3] M. Vidaud,et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. , 1999, Gastroenterology.
[4] J. Hoefs,et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.
[5] William M. Lee,et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.
[6] P. Marcellin,et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.
[7] S. Chevret,et al. Reinforced regiment of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomized trial , 1998 .
[8] Ming Liu,et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. , 1998, Journal of immunology.
[9] Aril Frydén,et al. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C , 1998, The Lancet.
[10] M. Alter,et al. Epidemiology of Hepatitis C , 2018, Clinical liver disease.
[11] S. Darby,et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C , 1997, The Lancet.
[12] P. Marcellin,et al. Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon- Therapy , 1997, Annals of Internal Medicine.
[13] L. Pagliaro,et al. The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis. , 1997, Journal of hepatology.
[14] T. Poynard,et al. Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration , 1996, Hepatology.
[15] P. Couzigou,et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. , 1995, The New England journal of medicine.
[16] M. Tong,et al. Clinical outcomes after transfusion-associated hepatitis C. , 1995, The New England journal of medicine.
[17] P. Schmid,et al. Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin , 1994, Journal of gastroenterology and hepatology.
[18] P. Bedossa,et al. Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients with Chronic Hepatitis C , 1994 .
[19] L. Stuyver,et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. , 1993, The Journal of general virology.
[20] F. Iber,et al. Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis , 1992 .
[21] J. Hoofnagle,et al. Long‐term follow‐up of patients with chronic hepatitis C treated with α‐interferon , 1992, Hepatology.
[22] Neil Kaplowitz,et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.
[23] P. Calès,et al. [Anti-fibrotic effects of interferons. Mechanisms of action and therapeutic prospects]. , 1997, Gastroenterologie clinique et biologique.